PDCD1 and neoplasm: In addition to immune checkpoints, other therapies targeting the immune system, such as the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, tumor vaccines, oncolytic viruses, and NK cell Ig-like receptor (KIR) in combination with PD-1/PD-L1 blockade are also under development.